News Release Details

Heron Therapeutics Appoints David L. Szekeres, SVP Business Development, General Counsel and Corporate Secretary

03/17/2016 |

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Mar. 17, 2016-- Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs, today announced the appointment of David L. Szekeres as Senior Vice President of Business Development, General Counsel and Corporate Secretary. Mr. Szekeres joins the Company today and will report to Barry D. Quart, Pharm.D., Chief Executive Officer of Heron.

“We are very excited that David has decided to join Heron, as he brings over 15 years of legal and industry experience, including a strong background in transactions,” commented Dr. Quart. “David will be a tremendous asset to the Company and is a welcome addition to the management team.”

Mr. Szekeres most recently served as General Counsel, Chief Business Officer, Principal Financial Officer, and Corporate Secretary at Regulus Therapeutics, Inc. In that role, Mr. Szekeres played a critical role in overseeing the company’s business, financial and legal responsibilities as it developed into a clinical-stage corporation. From March 2008 through February 2014, Mr. Szekeres served as Deputy General Counsel, Chief Mergers and Acquisitions Counsel and Assistant Corporate Secretary at Life Technologies Corporation. Prior to his tenure at Life Technologies, from 2001 through 2006, Mr. Szekeres served as Corporate Attorney at a number of law firms, including O’Melveny & Myers LLP and Latham & Watkins LLP and prior to this, he served as Senior Associate in Investment Banking at investment bank Robertson Stephens. Mr. Szekeres received a B.A. degree magna cum laude from the University of California, Irvine and a J.D. degree from Duke University School of Law.

About Heron Therapeutics, Inc.

Heron Therapeutics, Inc. is a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs. Heron is developing novel, patient-focused solutions that apply its innovative science and technologies to already-approved pharmacological agents for patients suffering from cancer or pain. Heron’s goal is to build on therapeutics with well-known pharmacology by improving their tolerability and efficacy as well as broadening their potential field of use. For more information, visit

Forward-Looking Statements

This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management’s expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, those associated with: whether the U.S. Food and Drug Administration (FDA) completes its review within the anticipated time period, whether the FDA approves the SUSTOL NDA as submitted or supports as broad of a labeled indication for SUSTOL as requested, the potential market opportunity for SUSTOL and expected timing of the commercial launch, the progress in the research and development of HTX-019, HTX-011 and our other programs, including the timing of preclinical, clinical, and manufacturing activities, safety and efficacy results from our studies that may not justify the pursuit of further development of our product candidates, acceptance of SUSTOL and new products generally, our financial position and our ability to raise additional capital to fund operations, if necessary, or to pursue additional business opportunities, strategic business alliances we may pursue or the potential acquisition of products or technologies, and our ability to grow our organization to sustain the commercial launch for SUSTOL, and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.

Source: Heron Therapeutics, Inc.

Heron Therapeutics, Inc.
Investor Relations Contact:
Jennifer Capuzelo, 858-703-6063
Associate Director, Investor Relations
Corporate Contact:
Barry D. Quart, Pharm D., 650-366-2626
Chief Executive Officer

Sign-Up for Email Updates

Receive news and updates on Heron’s latest innovations.